FDA Webview
X
about-us-banner

Pay Per View

Home / Pay Per View

QS, MDR Issues at Royal Philips China Plant

[ Price : $8.95]

FDA warns Royal Philips about Quality System and Medical Device Reporting violations at its medical device manufacturing facility ...

Annual Report on Postmarketing Requirements

[ Price : $8.95]

Federal Register notice: FDA makes available its annual report entitled Report on the Performance of Drug and Biologics Firms in C...

Colon Cancer Blood Test Goes to Panel

[ Price : $8.95]

Federal Register notice: An FDA advisory committee schedules a 5/23 meeting to review a Guardant Health PMA for its Shield blood t...

PMRs and PMCs Generally on Schedule: FDA Report

[ Price : $8.95]

FDA says most applicants completed or released most of the premarketing requirements or commitments reported in the agencys FY 202...

Get Involved with FDA on AI/ML: Attorneys

[ Price : $8.95]

Three Alston Bird attorneys urge companies regulated by FDA to engage with the agency on issues involving artificial intelligence ...

23 No-Longer-Marketed NDAs Withdrawn

[ Price : $8.95]

Federal Register notice: FDA withdraws the approval of 23 NDAs from multiple applicants because they are no longer marketed.

FDA Launches Home as a Healthcare Hub

[ Price : $8.95]

FDA launches a collaboration to develop a Home as a Healthcare Hub prototype to help patients, healthcare providers, and industry....

New Bladder Cancer Therapy Approved

[ Price : $8.95]

FDA approves an ImmunityBio BLA for Anktiva (nogapendekin alfa inbakicept-pmln) plus Bacillus Calmette-Gurin (BCG) for treating pa...

Sail Fusion Sacroiliac Fusion Device Cleared

[ Price : $8.95]

FDA clears a Sail Fusion 510(k) for its BowTie Sacroiliac Fusion System.

Pediatric Brain Tumor Therapy Approved

[ Price : $8.95]

FDA grants Day One Biopharmaceuticals accelerated approval for Ojemda (tovorafenib), a Type 2 RAF inhibitor for treating patients ...